Literature DB >> 29151323

Investigation of human leukocyte antigen in osteoarticular brucellosis

Sevim Gönen, Murat Dizbay, Oğuz Söylemezoğlu.   

Abstract

Background/aim: To determine the relationship between human leukocyte antigen (HLA) antigens and osteoarticular brucellosis by evaluating HLA Class I and II antigens in control subjects and patients developing osteoarticular brucellosis in Turkey.Materials and methods: The study included 28 patients with osteoarticular involvement diagnosed with brucellosis and 100 controls. The HLA Class I and II antigens were studied in isolated DNA samples using sequence-specific oligonucleotide procedure.
Results: The mean age of the 28 patients and 100 controls was 42.3 ± 20.2 years and 50.1 ± 16.3 years, respectively. When the frequency of HLA Class I was examined, HLA-A*02 and HLA-B*27 antigens were detected in 50% and 28.57% of the patients, respectively. However, there was no significant difference when compared to the control group. Among the HLA Class I antigens, HLA-Cw*10 was determined in 35.71% of the patients and 17% of the controls; the difference was significant (P = 0.039).
Conclusion: In the development of brucellosis, the frequency of HLA-Cw*10 among HLA Class I antigens was observed to be increased, and HLA-Cw*10 was considered likely to cause predisposition to brucellosis. Further studies to be performed on a higher number of patients and controls could demonstrate that genetic factors play a role in the diagnosis of osteoarticular brucellosis.

Entities:  

Keywords:  Brucellosis; human leukocyte antigen; polymerase chain reaction

Year:  2017        PMID: 29151323     DOI: 10.3906/sag-1612-105

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  1 in total

1.  Improved Early Detection of Focal Brucellosis Complications with Anti-Brucella IgG.

Authors:  Nannan Xu; Xiaomeng Dong; Yongyuan Yao; Yanyan Guan; Fengzhe Chen; Feng Zheng; Gang Wang
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 11.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.